Clinical Trials Logo

Impaired Glucose Tolerance clinical trials

View clinical trials related to Impaired Glucose Tolerance.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT05912348 Recruiting - Obesity Clinical Trials

The Effects of an Obesogenic Lifestyle in Recreationally Active, Young Adults

Start date: February 8, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to learn about the alterations insulin resistance and metabolic flexibility following a transition to an obesogenic lifestyle in fit young men. The main questions it aims to answer are: 1. Does the addition of excess carbohydrates when transitioning to a sedentary lifestyle promote insulin resistance in fit young men? 2. Does the addition of excess carbohydrates when transitioning to a sedentary lifestyle lower the body's ability to break down fats and carbohydrates in fit young men?

NCT ID: NCT05873322 Recruiting - Lymphoma Clinical Trials

Glucose Intolerance and Diabetes Related to Treatment With Steroids and PEG- Asparaginase in Children and Adolescents With ALL and Lymphoma

Start date: August 30, 2022
Phase:
Study type: Observational

The overall survival of acute lymphoblastic leukemia (ALL) and lymphoma in children and adolescents is above 90%. The survival rate has increased significantly during the last decades as a consequence of more intensive chemotherapy. This very toxic treatment results in severe acute toxicities and late effects, which is the biggest challenge today besides survival. The overall purpose of contemporary ALL treatment is to reduce the toxic treatment without compromising the excellent survival rates of these diseases. This study is a part of this. The researchers want to investigate the incidence of glucose intolerance and medicine induced diabetes during treatment for ALL and lymphoma with steroids (prednisolone or dexamethasone) and ± PEG-asparaginase. Steroids and asparaginase are used in the treatment of ALL and lymphomas, and both drugs may induce glucose intolerance or diabetes, especially when they are given concomitantly. The incidence and duration of increased blood glucose levels are not very well investigated, and especially not monitored continuously during treatment phases with steroids and +/- asparaginase, as the investigators want to do in this study. In the study the participants must have a glucose sensor attached under the skin, which continuously measures blood glucose during treatment. Moreover, blood samples are drawn several times to measure insulin sensitivity and beta cell function. The participants are children and adolescents (1.0-17.9 years) with newly diagnosed ALL or lymphoma treated at one of the four Danish pediatric oncology sites. Blood glucose levels are followed during treatment with steroids and PEG-asparaginase in these patient groups. The results may give rise to a new treatment guidelines for measuring and treating blood glucose in these patients. In the future this may help reduce the development of type 2 diabetes mellitus and metabolic syndrome in survivors of ALL and lymphoma.

NCT ID: NCT05387551 Recruiting - Clinical trials for Impaired Glucose Tolerance

CGM and Lifestyle Changes in Patients With Impaired Glucose Tolerance

Start date: December 1, 2022
Phase: N/A
Study type: Interventional

The incidence of type 2 diabetes (T2D) in children is increasing, paralleling the rising incidence of obesity. Preventing children and adolescents from developing T2D is critical. The health benefits of lifestyle modifications are well documented in this population, but success rates are low. Obesity in children and adolescents increases the risk of not only T2D but other complications as well, such as hypertension, dyslipidemias and more. The investigators hypothesize that having real-time glucose data with the use of a continuous glucose monitor (CGM) in obese patients with impaired glucose tolerance will improve adherence to lifestyle modifications. As a result, a decrease in body mass index (BMI) is expected with subsequent improvement in insulin sensitivity, thus reducing risk of obesity-related complications later in childhood/adolescence and adulthood.

NCT ID: NCT05354245 Recruiting - Insulin Resistance Clinical Trials

Using a Complex Carbohydrate Mixture to Steer Fermentation and Improve Metabolism in Adults With Overweight and Prediabetes (DISTAL)

DISTAL
Start date: September 8, 2022
Phase: N/A
Study type: Interventional

The purpose of this study is to investigate the effects of a fibre mixture added to a high-protein diet on metabolic, gut and brain health.

NCT ID: NCT05347030 Recruiting - Overweight Clinical Trials

Acupuncture for Impaired Glucose Tolerance in Overweight/Obese Population

Start date: October 6, 2022
Phase: N/A
Study type: Interventional

This is a prospective, multicenter, parallel-group, participants- and assessors-blinded randomized trial aiming to evaluate the effectiveness and safety of acupuncture in improving glucose metabolism for overweight/obese Participants with IGT, in comparison with sham acupuncture.

NCT ID: NCT05202002 Recruiting - Clinical trials for Diabetes Mellitus, Type 2

Decrease Type II Diabetes in Gestational Diabetes Population

Start date: March 1, 2021
Phase: N/A
Study type: Interventional

The goal of the study is to examine the impact of an educational video on the rate of breastfeeding in mothers who had gestational diabetes mellitus, and the rate of type-II diabetes mellitus diagnosed postpartum.

NCT ID: NCT05067621 Recruiting - Clinical trials for Type 2 Diabetes Mellitus

Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease

Start date: July 17, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this study is to understand the role of GLP-1 in the pathogenesis of T2D in youth and explore their potential salutary effects and ability to delay the progressive loss of ß-cell function and reduce hepatic steatosis in youth with prediabetes/new onset T2D and NAFLD.

NCT ID: NCT04938843 Recruiting - Clinical trials for Non-Alcoholic Fatty Liver Disease

Effect of F. Prausnitzii on Glycemic Control

Start date: August 16, 2021
Phase: N/A
Study type: Interventional

The microbiota is associated with a wide spectrum of diseases including diabetes and non-alcoholic fatty liver disease. In this study we will investigate if the bacteria F. prausnitzii, which is a part of the human gut microbiota, can improve metabolic parameters in subjects with impaired glucose control.

NCT ID: NCT04727580 Recruiting - Clinical trials for Impaired Glucose Tolerance

HSK7653 in Chinese Patients With Impaired Glucose Tolerance

Start date: March 29, 2021
Phase: Phase 2
Study type: Interventional

This study is being done to evaluate the efficacy, safety of HSK7653 in chinese participants with impaired glucose tolerance.

NCT ID: NCT04662866 Recruiting - Insulin Sensitivity Clinical Trials

Effects of Glucose Lowering Agents in South Asian Women With Impaired Glucose Tolerance or Impaired Fasting Glucose

DIASA3
Start date: February 10, 2021
Phase: Phase 2
Study type: Interventional

This study will test the effect of four common oral anti-diabetic agents on hepatic insulin sensitivity in South Asian women with impaired glucose tolerance or impaired fasting glucose. In a 12-week, double-blind, randomized controlled intervention trial, the following drugs will be tested head-to-head: Metformin, Pioglitazone, Empagliflozin and Linagliptin. Additional, exploratory outcomes include whole body insulin sensitivity, insulin secretion and other markers of glucose and lipid metabolism, measured by the euglycemic clamp with stable isotope tracer dilution, indirect calorimetry and CT-measurements of abdominal adipose tissue compartment volumes and hepatic and pancreatic volume and attenuation. The study is part of the DIASA - DIAbetes in South Asians - Research Programme, which aims to find ways to improve both prevention and treatment of type 2 diabetes in people of South Asian ethnicity.